ABS-201 Phase I/IIa progress, early safety/PK, AGA & endometriosis timelines, cash runway & catalysts—read now.

Q4 2025 Management View Peter Altman, CEO, highlighted that BioCardia now has complete and final data from three clinical trials of CardiAMP cell therapy, with the latest Phase III results presented ...

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...

Earlier this week, pharmaceutical company Pfizer and its partner Valneva announced that an experimental Lyme disease vaccine ...

High fat volume was linked to plaque presence and progression, but more work is needed to clarify clinical use.

Scientists from Puerto Rico and the U.S. advance earlier diagnosis and non-hormonal treatment for endometriosis, ...

Patients with adrenal insufficiency had significant improvements in bone and metabolic markers on a once-daily, low-dose ...

While ersodetug missed the Phase 3 primary endpoint of a reduction in hypoglycemia events, Rezolute argued that this goal was ...

A study found brain atrophy progresses more slowly with age in RRMS, highlighting the need to factor age into MS clinical ...

More people are accessing medicinal cannabis than ever expected, or the health system was designed for. And we’re failing patients.

Though TB remains the world's top infectious disease killer, there's cause for hope, Fred Hutch Cancer Center experts say.

What it is. AXPAXLI (OTX-TKI) is an investigational, bioresorbable intravitreal hydrogel implant designed to continuously ...